Special Issue

Microbial Infections and Sepsis: Pathophysiological Mechanisms and Therapeutic Approaches

Message from the Guest Editor

Sepsis survivors exhibit immune dysfunction. hematological changes, and an increased risk of infection. Clinical and experimental studies indicate that sepsis causes an immunosuppressive state characterized by diminished antimicrobial effector functions that increase susceptibility to infection. Sepsis-induced immunosuppression is multi-factorial and thought to be due to impaired cytokine secretion and diminished phagocytic activity of myeloid cells. However, researchers are still trying to discover whether and how sepsis impacts stem cell location and mobilization long-term, upon recovery from sepsis. In this Special Issue, we aim to accumulate original research articles and review articles related to pathophysiological mechanisms and therapeutic approaches in sepsis.

Guest Editor

Dr. Nirupam Biswas

New York State Department of Health, Wadsworth Center, Division of Environmental Health Sciences, Empire State Plaza, Albany, NY 12237, USA

Deadline for manuscript submissions

closed (31 August 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/211645

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).